Introduction
Methods
Study endpoint
Definitions
Statistical analysis
Results
Enrolment, baseline characteristics, survival and TR-assessment
Differences in baseline characteristics between the groups
Parameter | Severe TR at baseline (n = 148, 25.6%) | TR grade 0–2 at baseline (n = 431, 74.4%) | p value |
---|---|---|---|
Age at procedure [years] | 81.1 (76.6/84.9) | 78.5 (73.6/83.3) | < 0.001 |
Age > 70 years | 125 (96.2%) | 371 (86.3%) | 0.001 |
Female gender | 71 (54.6%) | 196 (45.6%) | 0.072 |
Height [cm] | 167 (162/172) | 169 (162/175) | 0.059 |
Weight [kg] | 70 (65.0/80.0) | 72.5 (65.0/84.0) | 0.229 |
BMI [kg/m2] | 25.5 (23.6/27.7) | 25.6 (23.1/28.0) | 0.980 |
NYHA III or IV (baseline) | 106 (93.0%) | 342 (89.3%%) | 0.287 |
Cardiovascular risk factors | |||
Obesity | 14 (10.9%) | 65 (15.4%) | 0.260 |
Art. Hypertension | 114 (87.7%) | 366 (85.1%) | 0.567 |
Diabetes mellitus | 32 (24.6%) | 123 (28.6%) | 0.434 |
Intervention parameters | |||
FMR | 76 (58.5%) | 241 (56.0%) | 0.686 |
DMR | 41 (31.5%) | 134 (31.2%) | 1.000 |
Mixed etiology | 13 (10.1%) | 55 (12.8%) | 0.447 |
Logistic Euroscore I [%] | 27.5 (19.0/40.0) | 26.0 (18.1/37.5) | 0.350 |
Comorbidities | |||
COPD | 14 (10.8%) | 65 (14.9%) | 0.311 |
PAH | 71 (54.6%) | 254 (59.2%) | 0.363 |
Atrial fibrillation | 109 (83.8%) | 287 (66.7%) | < 0.001 |
Renal insuffiency | 72 (55.4%) | 200 (46.6%) | 0.089 |
CAD | 81 (52.3%) | 279 (65.0%) | 0.602 |
History of myocardial infarction | 26 (20.0%) | 236 (29.3%) | 0.043 |
PAD | 24 (10.0%) | 44 (10.2%) | 1.000 |
History of stroke | 19 (14.6%) | 46 (10.7%) | 0.216 |
History of cardiac surgery | 29 (22.3%) | 107 (24.9%) | 0.641 |
History of surgical MVR/r | 2 (1.5%) | 7 (1.6%) | 1.000 |
Pacemaker | 42 (32.3%) | 123 (28.9%) | 0.443 |
Implantable cardioverter-defibrillator | 17 (13.1%) | 67 (15.6%) | 0.575 |
Medication | |||
Diuretics | 125 (96.9%) | 394 (91.8%) | 0.050 |
RAS-Blockers | 100 (77.5%) | 363 (84.6%) | 0.063 |
Betablockers | 105 (81.4%) | 354 (82.5%) | 0.793 |
Echocardiography | |||
LVEF [%] baseline/30 days/1 year | 47 (30/55) | 40 (30/55) | 0.073 |
50 (35/55) | 42 (30/55) | 0.030 | |
46 (39/55) | 45 (30/55) | 0.581 | |
MR (grade)* baseline | 0: 0.0% | 0: 0.0% | 0.683 |
1: 0.0% | 1: 0.0% | ||
2: 7.7% | 2: 2.2% | ||
3: 92.3% | 3: 97.8% | ||
MR (grade)* discharge | 0: 9.5% 1: 69.8% 2: 18.3% 3: 2.4% | 0: 7.2% 1: 62.4% 2: 26.4% 3: 4.1% | 0.030 |
MR (grade)* 30 days | 0: 4.5% 1: 50.0% 2: 39.8% 3: 5.7% | 0:8.3% 1:48.6% 2: 36.7% 4: 6.4% | 0.550 |
MR (grade)* 1 year | 0: 3.8% 1: 46.2% 2: 42.3% 3: 7.7% | 0: 4.4% 1: 52.0% 2: 36.8% 3: 6.9% | 0.435 |
TR (grade)* 30 days | 0: 1.2% 1: 22.1% 2: 31.4% 3: 45.3% | 0: 8.8% 1: 54.2% 2: 28.8% 3: 8.2% | < 0.001 |
Pmean MV [mmHg] baseline/30 days | 3.0 (2.0/4.0) 3.0 (2.0/4.0) | 2.0 (1.9/3.6) 3.0 (2.4/5.0) | 0.356 0.050 |
RV dysfunction baseline/30 days | 56.3% (76) | 30.7% (122) | < 0.001 |
45.9% (39) | 34.9% (111) | 0.077 | |
sPAP [mmHg] baseline/30 days | 53.0 (43.5/64.0) 45.0 (39.0/53.3) | 50.0 (45.0/60.0) 46.0 (40.0/54.0) | 0.278 0.392 |
TAPSE [cm] baseline/30 days | 1.6 (1.4/2.1) 1.8 (1.4/2.0) | 1.7 (1.4/2.1) 1.7 (1.5/2.1) | 0.316 0.569 |
Laboratory examinations | |||
Creatinine [mg/dl] baseline/30 days | 1.31 (1.00/1.81) | 1.23 (0.93/1.69) | 0.097 |
1.39 (1.06/1.91) | 1.23 (0.99/1.60) | 0.037 | |
BNP [pg/ml] baseline/30 days | 678 (435/1530) 478 (290/994) | 545 (245/1142) 481 (257/880) | 0.061 0.304 |
hsTnI [pg/ml] baseline/30 days | 19.1 (8.0/47.4) 13.7 (7.1/27.2) | 18.9 (7.4/46.7) 12.4 (5.4/27.7) | 0.846 0.494 |
Exercise testing | |||
6 min Walk-test [m/6 min] baseline/30 days | 152 (35/250) 311 (194/355) | 250 (127/351) 300 (225/395) | 0.108 0.315 |
Parameter | TR grade reduced (n = 132, 34.9%) | TR grade unchanged (n = 246, 65.1%) | p value |
---|---|---|---|
Age at procedure [years] | 81.1 (76.6/84.9) | 78.5 (73.6/83.3) | 0.724 |
Age > 70 years | 117 (88.6%) | 221 (89.8%) | 0.728 |
Female gender | 58 (43.9%) | 114 (46.3%) | 0.666 |
Height [cm] | 169 (162/174) | 168 (162/175) | 0.932 |
Weight [kg] | 73 (65.0/83.0) | 72.0 (65.0/83.0) | 0.657 |
BMI [kg/m2] | 25.7 (23.4/27.7) | 25.3 (22.9/27.8) | 0.586 |
NYHA III or IV (baseline) | 111 (91.0%) | 199 (88.4%%) | 0.585 |
Cardiovascular risk factors | |||
Obesity | 19 (14.5%) | 35 (14.3%) | 1.000 |
Art. Hypertension | 114 (86.4%) | 207 (84.1%) | 0.652 |
Diabetes mellitus | 34 (25.8%) | 64 (26.0%) | 1.000 |
Intervention parameters | |||
FMR | 71 (53.8%) | 1143 (58.1%) | 0.447 |
DMR | 47 (35.6%) | 71 (28.9%) | 1.000 |
Mixed etiology | 14 (10.6%) | 32 (13.0%) | 0.621 |
Logistic Euroscore I [%] | 22.0 (16.1/30.5) | 26.5 (18.5/37.9) | 0.015 |
Comorbidities | |||
COPD | 20 (15.2%) | 33 (13.4%) | 0.644 |
PAH | 82 (62.1%) | 145 (58.9%) | 0.583 |
Atrial fibrillation | 100 (75.8%) | 171 (69.5%) | 0.231 |
Renal insuffiency | 50 (37.9%) | 117 (47.8%) | 0.082 |
CAD | 76 (57.6%) | 160 (65.0%) | 0.181 |
History of myocardial infarction | 31 (23.5%) | 68 (27.6%) | 0.043 |
PAD | 9 (6.8%) | 24 (9.8%) | 0.445 |
History of stroke | 17 (12.9%) | 29 (11.8%) | 0.744 |
History of cardiac surgery | 24 (18.2%) | 56 (22.8%) | 0.355 |
History of surgical MVR/r | 2 (1.5%) | 3 (1.2%) | 1.000 |
Pacemaker | 39 (29.5%) | 75 (30.5%) | 0.907 |
Implantable cardioverter-defibrillator | 20 (15.2%) | 40 (16.3%) | 0.883 |
Medication | |||
Diuretics | 123 (93.2%) | 227 (92.3%) | 0.839 |
RAS-Blockers | 117 (88.6%) | 196 (79.7%) | 0.032 |
Betablockers | 109 (82.6%) | 207 (84.1%) | 0.771 |
Echocardiography | |||
LVEF [%] baseline /30 days/1 year | 45 (35/55) 50 (35/55) 45 (40/55) | 41 (30/55) 42 (30/55) 40 (30/55) | 0.142 0.011 0.272 |
MR (grade)* baseline | 0: 0.0% 1: 0.0% 2: 5.3% 3: 94.7% | 0: 0.0% 1: 0.0% 2: 7.7% 3: 92.3% | 0.376 |
MR (grade)* discharge | 0: 6.2% 1: 76.2% 2: 15.4% 3: 2.3% | 0: 7.4% 1: 58.7% 2: 29.7% 3: 4.1% | 0.002 |
MR (grade)* 30 days | 0: 8.3% 1: 59.8% 2: 30.3% 3: 1.5% | 0: 7.3% 1: 44.0% 2: 40.7% 3: 8.1% | 0.001 |
MR (grade)* 1 year | 0: 0.0% 1: 56.8% 2: 30.9% 3: 12.3% | 0: 5.9% 1: 48.0% 2: 42.1% 3: 3.9% | 0.530 |
TR (grade)* baseline | 1: 9.1% 2: 55.3% 3: 35.6% | 1: 54.9% 2: 29.3% 3: 15.9% | < 0.001 |
TR (grade)* 30 days | 0: 12.9% 1: 66.7% 2: 20.5% 3: 0.0% | 0: 4.4% 1: 38.1% 2: 33.7% 3: 23.8% | < 0.001 |
Pmean MV [mmHg] baseline/30 days | 3.0 (2.0/4.0) 3.0 (2.0/4.0) | 2.0 (1.0/3.1) 3.0 (2.5/5.0) | 0.105 0.048 |
RV dysfunction baseline/30 days | 35.0% (43) 30.5% (40) | 36.9% (86) 40.8% (109) | 0.716 0.048 |
sPAP [mmHg] baseline/30 days | 54 (47/60) 45 (39/52) | 50 (43/60) 47 (40/55) | 0.035 0.205 |
TAPSE [cm] baseline/30 days | 1.8 (1.4/2.2) 1.8 (1.5/2.1) | 1.6 (1.3/1.9) 1.7 (1.4/2.1) | 0.016 0.787 |
Laboratory examinations | |||
Creatinine [mg/dl] baseline/30 days | 1.20 (0.97/1.67) 1.21 (0.99/1.66) | 1.21 (0.93/1.68) 1.25 (1.00/1.66) | 0.885 0.524 |
BNP [pg/ml] baseline/30 days | 443 (238/965) 417 (236/646) | 594 (253/1470) 514 (278/1007) | 0.068 0.007 |
hsTnI [pg/ml] baseline/30 days | 14.3 (6.1/41.8) 13.3 (6.2/24.4) | 17.9 (6.6/40.0) 11.9 (5.4/28.0) | 0.621 0.540 |
Exercise testing | |||
6 min Walk-test [m/6 min] baseline/30 days | 400 (288/420) 316 (216/368) | 155 (0/390) 300 (238/367) | 0.040 0.347 |